MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-05-2025
NextCure General and Administrative Expenses 2011-2026 | NXTC
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses NextCure
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 15.7 M | 19.7 M | 21.7 M | 20.6 M | 17 M | 9.61 M | 3.41 M | 2.6 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 21.7 M | 2.6 M | 13.8 M |
Quarterly General and Administrative Expenses NextCure
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.81 M | 3.2 M | 3.73 M | - | 3.72 M | 4.08 M | 4.36 M | - | 4.61 M | 5.71 M | 5.42 M | - | 5.71 M | 5.3 M | 5.75 M | - | 4.91 M | 6.01 M | 4.85 M | - | 4.66 M | 4.67 M | 3.59 M | - | 2.62 M | 2.71 M | 1.66 M | - | 925 K | 866 K | 799 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 6.01 M | 799 K | 3.86 M |
General and Administrative Expenses of other stocks in the Biotechnology industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Apellis Pharmaceuticals
APLS
|
550 M | $ 20.29 | -1.98 % | $ 2.56 B |  USA |
 |
MorphoSys AG
MOR
|
78.3 M | - | 2.43 % | $ 254 M |  Germany |
 |
Aptorum Group Limited
APM
|
5.41 M | $ 0.8 | -5.29 % | $ 4.36 M |  China |
 |
Axsome Therapeutics
AXSM
|
63.3 M | $ 166.62 | 0.14 % | $ 8.29 B | USA |
 |
I-Mab
IMAB
|
900 M | - | - | $ 866 M | China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
1.4 B | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
7.15 M | - | -13.47 % | $ 169 M |  France |
 |
AbCellera Biologics
ABCL
|
83.2 M | $ 3.76 | -1.7 % | $ 1.12 B |  Canada |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
4.66 M | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
4.95 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Burford Capital Limited
BUR
|
99.3 M | $ 8.45 | -3.26 % | $ 1.38 B | Britain |
 |
Adverum Biotechnologies
ADVM
|
63.1 M | - | - | $ 86.2 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
25.8 M | - | - | - |  Russia |
 |
ARCA biopharma
ABIO
|
13.1 M | - | 1052.0 % | $ 415 M | USA |
 |
Acer Therapeutics
ACER
|
12.7 M | - | 2.71 % | $ 14 M | USA |
 |
Alpine Immune Sciences
ALPN
|
18 M | - | - | $ 2.17 B | USA |
 |
Acorda Therapeutics
ACOR
|
89.7 M | - | -24.86 % | $ 820 K | USA |
 |
Capricor Therapeutics
CAPR
|
12.8 M | $ 25.77 | -4.06 % | $ 690 M | USA |
 |
Acasti Pharma
ACST
|
7.17 M | - | 4.01 % | $ 150 M | Canada |
 |
CureVac N.V.
CVAC
|
100 M | - | - | $ 867 M | Germany |
 |
Aeterna Zentaris
AEZS
|
5.92 M | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
9.33 M | - | -10.17 % | $ 12.2 K | USA |
 |
Codexis
CDXS
|
55.1 M | $ 0.97 | -5.15 % | $ 71.2 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
47.9 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
17 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
29.7 M | - | 1.93 % | $ 17.4 M | USA |
 |
Agenus
AGEN
|
78.7 M | $ 3.15 | -5.69 % | $ 1.13 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
1.53 M | - | - | $ 7.46 M |  Israel |
 |
Akero Therapeutics
AKRO
|
37.9 M | - | - | $ 3.67 B | USA |
 |
Agios Pharmaceuticals
AGIO
|
180 M | $ 28.45 | -2.57 % | $ 1.65 B | USA |
 |
Advaxis
ADXS
|
12.2 M | - | -9.65 % | $ 45.9 M | USA |
 |
Akouos
AKUS
|
22.2 M | - | 0.23 % | $ 488 M | USA |
 |
Завод ДИОД
DIOD
|
19.7 M | - | - | - | Russia |
 |
Фармсинтез
LIFE
|
24.1 M | - | - | - | Russia |
 |
Albireo Pharma
ALBO
|
69.6 M | - | -0.23 % | $ 916 M | USA |
 |
Cellectis S.A.
CLLS
|
37.9 M | $ 3.65 | -3.95 % | $ 116 M | France |
 |
Alector
ALEC
|
54 M | $ 2.1 | -5.2 % | $ 216 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
12.7 M | - | 3.16 % | $ 1.9 M | USA |
 |
Aileron Therapeutics
ALRN
|
13.9 M | - | 10.36 % | $ 9.8 M | USA |
 |
Altimmune
ALT
|
21 M | $ 4.16 | -0.12 % | $ 295 M | USA |
 |
Teligent, Inc.
TLGT
|
23.4 M | - | -13.85 % | $ 16.1 M | USA |
 |
AlloVir
ALVR
|
42.9 M | - | 4.14 % | $ 49.1 M | USA |
 |
Viela Bio, Inc.
VIE
|
60.2 M | - | - | $ 2.91 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
7.08 M | - | -11.43 % | $ 502 K | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
63.1 M | $ 23.99 | 0.46 % | $ 2.93 B | USA |
 |
Amarin Corporation plc
AMRN
|
43.8 M | $ 13.89 | -0.32 % | $ 5.76 B |  Irlanda |
 |
AbbVie
ABBV
|
14 B | $ 231.88 | -1.0 % | $ 410 B | USA |
 |
Blueprint Medicines Corporation
BPMC
|
359 M | - | - | $ 8.14 B | USA |
 |
Applied Molecular Transport
AMTI
|
37.4 M | - | - | $ 10.1 M | USA |
 |
AIM ImmunoTech
AIM
|
13.1 M | $ 0.71 | -8.96 % | $ 34.1 M | USA |